Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting

CONSHOHOCKEN, Pa., Oct. 23, 2017 -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today presented preclinical results for MGL-3196 in a poster session at The Liver Meeting^® 2017, American Association for the Study of Liver Diseases (AASLD) being held at the Walter E. Washington Convention Center in Washington, DC, October 20 – 24, 2017.

MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist medication that is in Phase 2 development as a treatment for non-alcoholic steatohepatitis (NASH) and heterozygous familial hypercholesterolemia (HeFH). Top-line results from the Phase 2 studies for NASH and HeFH are expected by year-end and in the first quarter of 2018, respectively.

Key findings from the long-term high fat diet (HFD) mouse NASH model include:

• confirmation that prolonged treatment of mice with HFD generates fatty liver disease with a liver gene array profile consistent with activation of NASH inflammation and fibrosis pathways 

• findings that MGL-3196 potentially normalizes hepatic function in HFD animals, including restoration of normal hepatic metabolic regulation, liver size and histology without impacting tissues outside the liver 

• apparent reversal and prevention of the progression of lipid, inflammatory and fibrotic markers of NASH at human equivalent exposures of MGL-3196 


Poster # 1969: MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
Rebecca Taub, John Franc, Martha Kelly, Madrigal Pharmaceuticals, Villanova, PA
http://www.madrigalpharma.com/wp-content/uploads/2017/10/AASLD_poster_1969_final2.pdf

To view additional upcoming and archived events and presentations, please go to http://www.madrigalpharma.com/newsroom/presentations/

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq:MGDL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company’s lead candidate, MGL-3196, is a first-in- class, orally administered, small-molecule, liver- directed, thyroid hormone receptor (THR) β-selective agonist that is currently in Phase 2 development for NASH and heterozygous familial hypercholesterolemia (HeFH). For more information, visit www.madrigalpharma.com.

Forward-Looking Statements
This communication contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's clinical development of MGL-3196, the timing and outcomes of clinical studies of MGL-3196, and the uncertainties inherent in clinical testing. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal's filings with the U.S. Securities and Exchange Commission for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied.

Investor Contact:
Marc Schneebaum, Madrigal Pharmaceuticals, Inc. [email protected]  

Media Contact:
Mike Beyer, Sam Brown Inc. [email protected]  312-961-2502